AM Best Places Credit Ratings of PacificSource Health Plans Under Review with Negative Implications
The Credit Ratings (ratings) of PacificSource HP were placed under review with negative implications following the continued pressure on its government programs line of business, especially its Medicaid segment, as well as volatility in its earnings, capitalization and balance sheet metrics across its owned insurance entities. The under review status also considers potential pressure on its business profile and the rating enhancement it receives from its parent organizations, Pacific Health Associates (PHA) and Legacy Health.
The risk-adjusted capitalization, as measured by Best's Capital Adequacy Ratio (BCAR), is assessed as very weak and the overall balance sheet strength of PacificSource HP is assessed as weak. The company manages capital to the minimum state regulatory requirements. Capital and surplus saw a decrease through year end, significantly impacted by a total premium deficiency reserve (PDR) of almost $75 million booked for 2025, consisting of a $44 million PDR for Medicare Advantage and a $30 million PDR for Medicaid, along with worsened results in the third and fourth quarters of 2024, largely related to increased Medicaid utilization. The reported year-end 2024 losses and capital levels were below projections provided at year end when AM Best's last ratings assessment was completed (see AM Best Downgrades Credit Ratings of PacificSource Health Group Subsidiary). Additional PDR changes are expected and could cause additional volatility throughout 2025.
The projected 2025 results are still unfavorable; however, AM Best notes that there has been a capital contribution from its holding company, PacificSource, of $15 million, which was made during first-quarter 2025, and additional capital bolstering and operating performance initiatives are in progress as management believes are needed. Furthermore, capital contributions from PacificSource are planned for the remainder of 2025. AM Best will continue to monitor the appropriateness and adequacy of these initiatives to meet BCAR requirements and also in relation to operating performance and required reserve adjustments, over the next one to two quarters of 2025 at a minimum.
The amount of rating enhancement afforded through lift from one of its two 50% owners, Legacy Health, could also be impacted, as well, as Legacy Health has no immediate plans to provide explicit capital support to its insurance subsidiaries to support their recent losses and capital declines.
The ratings will remain under review with negative implications while AM Best monitors the organization's financial condition and discusses corrective action plans for bolstering risk-adjusted capitalization and operating performance in the near-to-intermediate timeframe. Additional losses or lack of improvement through organic means and/or potential additional capital support from either or both parents could result in further negative rating actions.
This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.
AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.
Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250513085996/en/
Contacts
Michael Sweeney Financial Analyst +1 908 882 2384 michael.sweeney@ambest.com
Joseph Zazzera Director +1 908 882 2442 joseph.zazzera@ambest.com
Christopher Sharkey Associate Director, Public Relations +1 908 882 2310 christopher.sharkey@ambest.com
Al Slavin Senior Public Relations Specialist +1 908 882 2318 al.slavin@ambest.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
13 minutes ago
- CNBC
UnitedHealth says it is facing DOJ investigation over Medicare billing practices
UnitedHealth Group revealed Thursday it is facing a Justice Department investigation over its Medicare billing practices. It comes after the Wall Street Journal reported in May that the Department of Justice is conducting a criminal investigation into the health-care giant over possible Medicare fraud. In response at the time, the company said it stands "by the integrity of our Medicare Advantage program." In July, the Journal also reported that the DOJ interviewed several doctors about UnitedHealth's practices and whether they felt pressured to submit claims for certain conditions that bolstered payments from the Medicare Advantage program to the company. That marked the second time this year that the insurer's Medicare Advantage business has come under federal scrutiny. The Journal also reported in February that the DOJ is conducting a civil investigation into whether the company inflated diagnoses to trigger extra payments to its Medicare Advantage plans. But in March, UnitedHealth moved a step closer to ending a yearslong legal battle with the DOJ that began with a whistleblower who alleged the company illegally withheld at least $2 billion through the Medicare Advantage program. A special master assigned to the case by the judge issued a recommendation in favor of UnitedHealth, saying the DOJ lacked evidence. UnitedHealthcare's Medicare and retirement segment, which includes the Medicare Advantage business, is UnitedHealth Group's largest revenue driver, raking in $139 billion in sales last year. The update in the probe comes after a tumultuous last year for UnitedHealthcare, the nation's largest and most powerful private health insurer. Shares of UnitedHealthcare's parent company, UnitedHealth Group, are down more than 42% for the year after it suspended its 2025 forecast amid skyrocketing medical costs, announced the surprise exit of former CEO Andrew Witty and grappled with the reported probe into its Medicare Advantage business. The company's 2024 wasn't any easier, marked by a historic cyberattack and the torrent of public blowback after the murder of UnitedHealthcare's CEO Brian Thompson.
Axios
3 hours ago
- Axios
This Medicare change is giving hospitals heartburn
Hospitals found an unpleasant surprise buried in a proposed 913-page Medicare payment rule last week: a Trump administration plan to speed up — by a decade — the recovery of $7.8 billion in improper cuts to facilities' discount drug reimbursement. Why it matters: The change comes out to over $1 billion less than expected in Medicare payment next year, with more reductions going forward. Reduced Medicare payment would be a double whammy, hitting just as sweeping changes to Medicaid are expected to put new financial pressures on facilities. "It's piling on," Maureen Testoni, CEO of 340B Health, which advocates on behalf of hospitals that participate in the discount drug program, told Axios. Facilities that rely on these federal programs are "definitely going to reach unsustainability." Some industry groups are already threatening to sue to halt the plan if it's finalized, saying it punishes hospitals for a mistake that Medicare itself made between 2018 and 2022. The new timeline for clawbacks would jeopardize hospitals' ability to care for patients in need, Testoni said in a statement. Follow the money: The clawback stems from a Supreme Court ruling that overturned a nearly 30% cut the first Trump administration made in payments to safety-net providers in the 340B federal discount drug program, after research showed some could profit inappropriately off the program. Medicare repaid $9 billion to make the affected hospitals whole early last year. The problem was that Medicare budgeting anticipated future savings from the 30% cut boosted pay for hospital outpatient services other than dispensing drugs. To avoid adding to total Medicare spending, the Biden administration devised a plan to claw back $7.8 billion in increased reimbursements from hospitals over 16 years. Now, the administration wants to reduce that timeline by a decade, arguing the quicker process would make the burden on hospitals more closely reflect the benefits they previously received. A more drawn-out process could also be complicated by hospital closures, it said. That translates into a bigger annual clawback for hospitals already operating on tight margins. The Centers for Medicare and Medicaid Services also notified hospitals last week that it plans to conduct a survey early next year on their costs for acquiring drugs, including rebates and discounts that hospitals receive under the federal 340B discount drug program. The notice doesn't explicitly say that the survey will be used to justify future cuts to hospitals' reimbursement. But industry executives say that's the subtext, especially in light of the 2022 Supreme Court decision. Between the lines: Hospital participation in 340B has grown significantly over the past two decades. Nonprofit and public hospitals that qualify for the program say it enables them to provide charity care. But critics say it's gotten too big and charge that some hospitals abuse the program. Conservative think tanks that have the Trump administration's ear, like Paragon Health Institute, have recommended overhauling the way Medicare pays for discounted drugs. What they're saying: The American Hospital Association hinted it could sue the administration if it moves forward with accelerated clawbacks. "The proposed recoupment is both illegal and unwise, and it should not be finalized," Ashley Thompson, AHA's senior vice president of public policy analysis and development, said in a statement. The Association of American Medical Colleges also said that speeding up the clawbacks "will have catastrophic effects on patients nationwide." What to watch:"We expect significant pushback in the comments to this proposed rule and that the final rule may be less aggressive," Chris Meekins, managing director at Raymond James and health official in the first Trump administration, wrote in an analyst note.
Yahoo
4 hours ago
- Yahoo
Why a Democrat says he can beat Laurel Lee in Tampa congressional race
Another Democrat is stepping up to challenge Republican U.S. Rep. Laurel Lee. Darren McAuley, a former Veterans Affairs doctor with about a quarter century of experience as a military flight surgeon, announced he is entering the race. The married father of three says he's running first and foremost on affordability. 'I can win the district because Republicans have unfortunately made it clear that they are not going to do what's required to take care of people,' McAuley said in an interview. Lee has represented Congressional District 15 — which covers part of Hillsborough, Polk and Pasco counties — since 2023. The area leans Republican and the seat is up for election in 2026. McAuley criticized Lee's vote in support of President Donald Trump's signature One Big Beautiful Bill Act, which, among other things, made cuts to Medicaid and food assistance programs and extended tax cuts from Trump's first administration. The bill is projected to explode the federal deficit. (Republicans have contended the economic growth encouraged by the tax cuts will offset the decrease in federal revenue.) He also said Lee has not done enough to push back on Trump's stance on tariffs, which McAuley argues are going to lead to more expensive consumer goods for Central Floridians. In response to McAuley's criticisms, a spokesperson for Lee defended her record. The One Big Beautiful Bill Act 'delivered real results for Central Florida families by stopping the largest tax increase in American history, eliminating wasteful spending, and protecting essential programs that our seniors and veterans rely on,' the spokesperson, Landon Hoffman, wrote in a text. Later, he added, 'What some call a 'trade war,' we see as a long-overdue defense of U.S. workers.' Lee won reelection in 2024 by 12 points over Democrat and former Hillsborough County Commissioner Pat Kemp. But that race was not without turbulence. After she was the only member of Florida's congressional delegation to endorse Gov. Ron DeSantis for president over Trump, Trump briefly and publicly explored endorsing a primary challenger to Lee in 2024. No such major challenger materialized, and Lee endorsed Trump for president after DeSantis dropped out. Lee, who previously served as Florida's top election official, has filed to run again with the state, as have two other Democrats, Robert People and Jose Engell. In a survey published on Ballotpedia, People, an Army veteran, said he's running to protect Social Security, expand access to abortion and increase teacher salaries nationwide. His federal campaign committee has raised about $8,700. In that same survey, Generation Z candidate Engell said he's running on Medicare for All and paid maternity leave. A campaign committee supporting his run has not filed any receipts, federal campaign finance records show. Although Congressional District 15 has long been coveted by Democrats, it's slipped away from them in recent election cycles. McAuley, who lives just outside the district, hopes to reverse the trend by showing voters he believes in common sense above party politics. 'What's bringing me into this race is seeing the caliber of leadership…lacking in Congress,' he said. 'We need to focus on serving the needs of the people.' This story may be updated. Check back at
